(Press-News.org) Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.
The phase 1 clinical trial, which is recruiting 20 qualifying participants, will evaluate suramin -- a century-old drug still used for African sleeping sickness -- as a novel treatment for children with a diagnosis of Autism Spectrum Disorder (ASD). Previous published research by Robert K. Naviaux, M.D., Ph.D., professor of medicine, pediatrics and pathology at UC San Diego School of Medicine, and colleagues reported that a single injection of suramin reversed symptoms of ASD in mouse models.
This trial is the first to test suramin in children with ASD.
'Autism affects 1 to 2 percent of children in the United States,' said Naviaux, co-director of the Mitochondrial and Metabolic Disease Center at UC San Diego. 'Hundreds of genetic and environmental factors have been shown to increase the risk of ASD, but treatment options for the core symptoms are limited. To date, there are no medications that can cure ASD, and very few that can improve its core symptoms.'
To participate in the study, a child must be a boy between the ages of four to 17 years and have been diagnosed with ASD by a psychologist or physician. He must be a resident of San Diego County and cannot have a known genetic cause of mutation (such as Fragile X syndrome) or be taking any prescription medications. He cannot have been hospitalized within the last two months or be planning to begin any new medical treatments during the time of the study. The study will involve 10 to 12 clinical visits over three to four months for each child.
All testing and treatment will occur in San Diego County. Participants who complete the trial will be compensated for their time.
In the trial, suramin will be given as a single dose through an intravenous line. Half of the participating children will receive suramin, half will receive a placebo (saline infusion). Behavioral and medical tests will be conducted before and after treatment, and include some blood and urine analyses.
The trial is the first clinical investigation of a novel theory, advanced by Naviaux, that posits autism may be a consequence of abnormal cell communication resulting from abnormal activation of the cell danger response.
Cells threatened or damaged by microbes, such as viruses or bacteria, or by physical forces or by chemicals, such as pollutants, react defensively, a part of the normal immune response, Naviaux said. Their membranes stiffen. Internal metabolic processes are altered - most notably mitochondria, the cells' critical 'power plants' -- resulting in activation of the cell danger response and reduced communications between cells.
Naviaux said the cell danger response theory does not contradict other research regarding the causes of autism. Rather, it offers another perspective and, perhaps, a new therapeutic target.
Because suramin treatment for autism is unprecedented, Naviaux emphasized it is not known whether the drug will produce any beneficial effect in humans. He noted that suramin, as currently constituted, cannot be used for more than a few months without a risk of toxicity in humans and that it is not available as an ongoing treatment.
'So even if participants show benefit during the trial, it will not be possible to continue treatment after the study,' said Naviaux. 'However, if the study is successful, they may be eligible for the next suramin study.'
INFORMATION:
Contact:
Jeanne Townsend
jtownsend@ucsd.edu
858-246-1932
Suzanne Goh
sgoh@gohmd.com
858-304-6440
Alan Lincoln
alincoln@alliant.edu
858-444-8823
Please provide child's date of birth and gender in emails. Prior to trial enrollment, a clinician's report verifying autism diagnosis will be required.
MADISON, Wis. -- Fragile X syndrome is the most common inherited intellectual disability and the greatest single genetic contributor to autism. Unlocking the mechanisms behind fragile X could make important revelations about the brain.
In a new study published June 4 in the journal Cell Reports, researchers from the University of Wisconsin-Madison Waisman Center and Department of Neuroscience show that two proteins implicated in fragile X play a crucial role in the proper development of neurons in mice. They also show that while the two proteins act through distinct mechanisms ...
Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD).
Their study, which reveals new information about the role of abdominal fat in patients with CAH and points to a need for targeted prevention and therapeutics to avoid these adverse effects, will be published online June 10, 2015 by The Journal of Clinical Endocrinology ...
SAN FRANCISCO - Innovative vaccine and tumor research will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The meeting takes place Monday, June 8- Wednesday, June 10 at the San Francisco Marriott Marquis.
This year's conference is organized into five meeting workstreams: Chemistry, Manufacturing, and Controls (CMC) including Formulation, Characterization, Stability and Biomanufacturing; Research and Discovery; Clinical Pharmacology, Pharmacokinetic/Pharmacodynamic (PK/PD), and Bioanalytics; Regulatory; ...
Was it a massive migration? Or was it rather a slow and persistent seeping of people, items and ideas that laid the foundation for the demographic map of Europe and Central Asia that we see today? The Bronze Age (about 5,000 - 3,000 years ago) was a period with large cultural upheavals. But just how these upheavals came to be have remained shrouded in mystery.
Assistant Professor Morten Allentoft from the Centre for GeoGenetics at the Natural History Museum of Denmark at the University of Copenhagen is a geneticist and is first author on the paper in Nature. He says:
- ...
An international team of scientists has found a dramatic ice sheet collapse at the end of the ice age before last caused widespread climate changes and led to a peak in the sea level well above its present height.
The team found the events 135,000 years ago caused the planet to warm in a different way to the end of the most recent ice age about 20,000 to 10,000 years ago.
The findings will help scientists understand the processes that control Earth's dramatic climate changes, said the leader of the study, Dr Gianluca Marino of The Australian National University (ANU).
"We ...
Several neurodegenerative disorders are caused by aggregates of a single protein known as alpha-synuclein. In collaboration with CNRS and the University of Antwerp, KU Leuven neurobiologists have discovered that the shape of these aggregates - 'cylinders' or 'ribbons' - determines whether a patient develops Parkinson's disease or Multiple System Atrophy, respectively.
Typical of neurodegenerative disorders is the disrupted communication between brain cells together with a loss of cells in specific brain regions. For some brain diseases this phenomenon is linked to a ...
The discovery of how a group of bacteria rapidly adapts to changing growth conditions could have implications for future antibiotic development, according to research at the University of Oxford and the University of York.
Led by Professor Colin Kleanthous at Oxford and Dr Christoph Baumann at York, the research which also involved key collaborators Mark Sansom at Oxford and Jacob Piehler at the University of Osnabrück, is published in Nature.
Gram-negative bacteria are a major cause of disease, in part because they have a robust outer membrane that protects ...
A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept.
The ixekizumab groups showed quick and extensive improvements in their condition, outperforming the groups on placebo or etanercept. Around ...
wo NASA satellites provided a look inside and outside of Tropical Cyclone Ashobaa. NASA and JAXA's GPM satellite observed rainfall rates and cloud heights identifying powerful thunderstorms within the cyclone, and NASA's Aqua satellite provided an overall look at Ashobaa's cloud extent.
The Global Precipitation Measurement (GPM) core observatory had an excellent view of Tropical Cyclone Ashobaa in the Arabian Sea over on June 8, 2015 at 2131 UTC (5:31 p.m. EDT). As expected, Tropical Cyclone Ashobaa was more powerful than when seen by GPM earlier in the day. GPM's Microwave ...
Genetically modified fish that overexpress growth hormone have been created for more than 25 years, but unlike many domesticated crops, transgenic fish have yet to enter commercial production. Because of the difficulty inherent in eradicating an established fish population, efforts are under way to model the threat posed by possible invasions.
In an article for an upcoming issue of BioScience, a team of government and academic researchers, led by Robert Devlin of Fisheries and Oceans Canada, examined the possible outcomes of an accidental release of transgenic fish. Their ...
